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Summary 
 
The Centers for Disease Control and Prevention's Arctic Investigations Program (AIP) in Anchorage, Alaska, 
maintains a statewide surveillance system for invasive diseases caused by Streptococcus pneumoniae, 
Haemophilus influenzae,  Neisseria meningitidis, and Groups A and B Streptococci.  Laboratories throughout 
the state are requested to send to AIP any isolates of these organisms recovered from a blood culture, CSF, or 
other normally sterile site. Isolate identification is confirmed and, when appropriate, serotyped and tested for 
antimicrobial susceptibility.  The objectives of this system are to provide information on disease rates within 
the state, monitor the emergence of antimicrobial resistance, and to monitor the effectiveness of implemented 
vaccine programs, such as the 23-valent pneumococcal polysaccharide vaccine, the 7-valent pneumococcal 
conjugate vaccine and Haemophilus influenzae type b vaccines. 
 






In 2000, the total number of cases of invasive disease caused by these organisms reported to AIP were 125 S. 
pneumoniae, 16 H. influenzae, 9 N. meningitidis, 18 Group A Strep and 18 Group B Strep.  Alaska Native 
populations had higher rates of disease than non-Native populations in all invasive disease except those 
caused by Group B Strep.  Rates of invasive pneumococcal disease were highest in the YK Delta and 
Kotzebue regions; H. influenzae rates were highest in Bristol Bay and Norton Sound.  Rates for each 
organism by region are presented in the following table. 
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Group A Strep 
n (rate*) 
Group B Strep 
n (rate*) 
Anchorage 69 (17.1) 9 (2.2) 7 (1.7) 12 (3.0) 15 (3.7) 
Arctic Slope 1 (15.8) 0 (0) 0 (0) 1 (15.8) 0 (0) 
Bristol Bay 1 (13.4) 2 (26.8) 1 (13.4) 0 (0) 0 (0) 
Interior 14 (14.5) 2 (2.1) 1 (1.0) 2 (2.1) 3 (3.1) 
Kotzebue 6 (75.3) 0 (0) 0 (0) 0 (0) 0 (0) 
Norton Sound 2 (21.7) 2 (21.7) 0 (0) 0 (0) 0 (0) 
Southeast 8 (11.0) 0 (0) 0 (0) 1 (1.4) 0 (0) 
YK Delta 24 (102.5) 1 (4.3) 0 (0) 2 (8.5) 0 (0) 
Total 125 (19.9) 16 (2.6) 9 (1.4) 18 (2.9) 18 (2.9) 




AIP conducts statewide surveillance of invasive Streptococcus pneumoniae, Haemophilus influenzae, 
Neisseria meningitidis, and Groups A and B Streptococcus.  This program is part of a passive, laboratory-
based surveillance system in which laboratories from all hospitals throughout the state are encouraged to 
participate.  The population included in the AIP surveillance is the State of Alaska, a total of 626,932 persons 
(Census 2000).  Case detection occurs year-round as participating laboratories send isolates recovered from 
sterile sites to the AIP lab in Anchorage, accompanied by basic demographic and clinical information on the 
cases.  Materials and forms for isolate shipment and data collection are provided to each lab by AIP.  At year-
end, AIP asks that each laboratory review their records and provide information on any cases that may have 
been overlooked.  In 2000, 21 of the 25 labs in Alaska participated in the invasive disease surveillance 
system, either by sending isolates to the AIP lab throughout the year, conducting year-end record reviews, or 
both.  
 
AIP defines a case of invasive Streptococcus pneumoniae, Haemophilus influenzae, Neisseria meningitidis, or 
Groups A and B Streptococcus as an isolate of the bacteria from a normally sterile site, including blood, 
cerebrospinal fluid, pleural fluid, peritoneal fluid or joint fluid that has been taken from a resident of Alaska.  
In addition, for Group A Streptococcus, isolates are requested from deep tissue infections such as might be 
collected from surgical debridement of cases of necrotizing fascitis. 
 
 




Between January 1 and December 31, 2000, AIP received a total of 110 pneumococcal isolates.  An 
additional 15 cases were detected through year-end follow up with participating labs throughout the state, for 
a total of 125 cases of invasive pneumococcal disease.  The result is an overall invasive pneumococcal case 
rate of 19.9/100,000 persons per year for the state of Alaska in the year 2000.   The Alaska rate is similar to 
the Active Bacterial Core Surveillance (ABCs) 2000 national projected rate of 20.7/100,000 (Active Bacterial 
Core Surveillance (ABCs) Report Emerging Infections Program Network Streptococcus pneumoniae, 2000).  




Invasive Streptococcus pneumoniae cases were identified in every month of 2000.  Nineteen cases occurred 
in the month of September, the highest number of cases occurring in any 1-month period in 2000.  The 
September cases occurred in 9 different communities and included 10 different serotypes.  Infected 
individuals ranged in age from infancy to 65 years.   Of note, 13 of the 19 cases occurred in the time period 
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September 20 – 29.  Four of the infections identified during this month resulted in death, producing a case-
fatality rate of 21% for September.  Thirty-one percent of all cases of pneumococcal-related mortality in 2000 
were identified in September. 
 
















































































Although the Alaska Native population comprises only 17% of the state population (Census 2000:  Alaska 
Natives 108,187, non-Natives 518,745), 47% of all reported S. pneumoniae cases occurred among this group 
in 2000.  A total of 59 cases occurred among Alaska Natives, resulting in an age-adjusted rate for Alaska 
Natives of 55.3/100,000 persons per year.  In contrast, 53% of cases occurred among the non-Native 
population, for a non-Native age-adjusted rate of 5.9/100,000 persons per year (66 cases).  The age-adjusted 
rate ratio of disease for the Alaska Native population compared with the non-Native population is 9.4.   
 
Invasive Streptococcus Pneumoniae Cases, by Race - Alaska, 2000 
Race* Cases 
No.  (%) 
Age Adjusted 
Rate 
% Male Deaths 
No. (%) 
Alaska Native 59 (47%) 55.3 56% 1 (8%) 
Non-Native 66 (53%) 5.9 53% 12 (92%) 
Total 125 (100%) 19.9 54% 13 (100%) 




Most cases of invasive pneumococcal disease (69) were reported in the Anchorage area, however, rates of 
disease are highest in the YK Delta and Kotzebue, 102.5/100,000 persons per year and 75.3/100,000 persons 
per year respectively. 
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Rates of Invasive Pneumococcal Disease, 
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Cases occurred in all age groups and ranged from 25 days to 98 years of age.  Almost half of all invasive 
pneumococcal disease in Alaska occurred among the high-risk age groups, those under the age of 2 and those 
greater than 65 years.  Overall, 29% of cases occurred among children <2 years.   
 
 


































































The rate of invasive pneumococcal disease for males was 21.0/100,000 persons per year (68 cases).  For 
females, the rate of invasive pneumococcal disease was slightly lower at 18.8/100,000 persons per year (57 
cases). 
 
Census 2000 data:  Male population 324,112, Female population 302,820 
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Clinical Presentation 
 
Primary Clinical Presentations of Invasive 
Pneumococcal Disease -  Alaska, 2000
11

















































































          *Septicemia of unknown focus            
 
 
The primary clinical presentation was determined by a review of the discharge diagnoses indicated in each 
patient’s chart.  In cases with multiple discharge diagnoses, the most serious diagnosis related to the 
pneumococcal infection was recorded as the primary clinical. In 13 cases, a secondary pneumococcal-related 
presentation was noted:  12 patients experienced pneumonia and 1 patient experienced septic arthritis in 
addition to the primary presentation.   
 
Primary Clinical Presentations of Invasive Pneumococcal Disease in Alaska, 2000 
 
 
The most frequent source of a positive culture was blood, which was used to identify 92% of the 125 cases.  
CSF was the positive site for 5.6% of cases and 1 case each was identified through a positive culture of 
pleural fluid and joint fluid.  One additional case was identified from an unspecified sterile site.  
 
Presentation No. Cases (%) % Male No. Deaths 
Meningitis 11 (9%) 55% 1 
Empyema 4 (3%) 50% 1 
Septic Shock 3 (2.4%) 0% 1 
Pericarditis 1 (0.8%) 100% - 
Epiglottitis 1 (0.8%) 0% - 
Cellulitis 1 (0.8%) 0% - 
Pneumonia 67 (54%) 54% 5 
Septic Arthritis 2 (1.6%) 50% - 
Bacteremia 9 (7%) 58% 1 
Septicemia 
(unknown focus) 
26 (20%) 58% 4 
Total 125 54% 13 
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Mortality 
 
Invasive Pneumococcal Mortality, by Age Group - 
Alaska, 2000


























In 2000, the overall case-fatality rate for S. pneumoniae in the state of Alaska was 10.4% (13 deaths out of 
125 cases).   The non-Native case-fatality rate was 18% (12 deaths), compared with the case-fatality rate for 
Alaska Natives of 1.7% (1 death).  The case-fatality rate for adult non-Native cases was 29%, or 12 of 41 
cases.  The relative risk of dying while infected with invasive Streptococcus pneumoniae for non-Native 
adults, compared with Alaska Native adults was 2.8 after adjusting for age.   
 
The highest mortality occurred in the 65+ year old age group, in which 61.5% of all pneumococcal deaths 
occurred.  Together, 92% of the mortality occurred among those over the age of 45.   No deaths were reported 




Serotyping of invasive pneumococcal isolates is performed at AIP using internationally standardized 
methods.  Serotype identification is based on the organism's polysaccharide capsule which is a principle 
virulence factor for pneumococci.   This information provides a way to subtype organisms and to determine if 
the infection was due to a type that could be prevented by use of one of the two available pneumococcal 
vaccines. Serotyping was performed on 110 of the 125 pneumcoccal cases detected in Alaska in 2000.  
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Invasive Pneumococcal Serotype Distribution, by Race and Age Group – Alaska, 2000 
  Alaska Native Non-Native* 
Serotype Total 
N (%) 
<2 2-18 >18 All Ages <2 2-18 >18 All Ages 
14 19 (17.3) 9 1 - 10 3 1 5 9 
04 13 (11.8) 2 5 3 10 - - 3 3 
07F 10 (9.1) - - 2 2 - 3 5 8 
09V 9 (8.2) 2 1 1 4 1 1 3 5 
19F 7 (6.4) - 2 - 2 3 - 2 5 
03 6 (5.5) - - 3 3 - - 3 3 
01 5 (4.5) - 1 1 2 - 2 1 3 
22A 1 (0.9) 1 - - 1 - - - 0 
22F 5 (4.5) - - 1 1 1 - 3 4 
06A 4 (3.6) 1 - - 1 1 - 2 3 
18C 4 (3.6) - 1 - 1 - 2 1 3 
06B 4 (3.6) - - - 0 4 - - 4 
23F 3 (2.7) - 1 - 1 - - 2 2 
11A 2 (1.8) - - 1 1 - - 1 1 
16F 2 (1.8) - - 1 1 - - 1 1 
19A 2 (1.8) 1 - - 1 1 - - 1 
09N 1 (0.9) - - - 0 - - 1 1 
10A 1 (0.9) - - - 0 - - 1 1 
13 1 (0.9) - - - 0 - - 1 1 
15A 1 (0.9) 1 - - 1 - - - 0 
17F 1 (0.9) - - 1 1 - - - 0 
20 1 (0.9) - - 1 1 - - - 0 
33F 1 (0.9) - - 1 1 - - - 0 
35B 1 (0.9) - - - 0 - - 1 1 
35F 1 (0.9) - 1 - 1 - - - 0 
38 1 (0.9) - - - 0 - - 1 1 
NT* 4 (3.6) 2 - 2 4 - - - 0 
Total 110 19 13 18 50 14 9 37 60 





Two vaccines are licensed for prevention of pneumococcal disease.  The 23-valent polysaccaride vaccine is 
recommended in Alaska for all persons 55 years and older, and for persons over age 2 who are at higher risk 
for pneumococcal disease. Revaccination is recommended after 6 years.  In 2001, the pneumococcal 
conjugate vaccine was included in the Alaska childhood vaccination schedule.  This vaccine provides 
protection against the 7 most common pneumococcal serotypes causing invasive disease among children 
(types 4, 6B, 9V, 14, 18C, 19F, 23F).  The tables below show the proportion of invasive infections from 2000 
that were due to serotypes found in these vaccines. 
 
Proportion of Invasive Isolates Contained in the PCV7 Vaccine, by Age Group and Race – Alaska, 2000 
Age (yrs) Alaska Native (%)* Non-Native (%)* Total (%)** 
<2 13 (76%) of 17 11(79%) of 14  24 (77%) of 31 
2-4 5 (83%) of 6 2 (67%) of 3 7 (78%) of 9 
5+ 10 (43%) of 23 18 (43%) of 43 28 (43%) of 66 
Total 28 (61%) of 46 31 (52%) of 60 59 (56%) of 106 
*The percentage of isolates with a serotype in the PCV7 vaccine, out of all isolates for that age and racial group. 
**The percentage of isolates with a serotype in the PCV7 vaccine, out of the total number of isolates for that age group (total n=106). 
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Potentially Vaccine Preventable Invasive Illness 
 < 2 years 2 – 4 5 - 54 55 - 64 65+ Total 
PCV7 24 (77%) 7 (78%) 17 (45%) 5 (56%) 6 (32%) 59 (56%) 
Ps23V 27 (87%) 9 (100%) 36 (95%) 8 (89%) 14 (74%) 94 (89%) 
Total 31 9 38 9 19 106 
Note: The number in parentheses is the percentage of cases with a serotype in the indicated vaccine,  




Pneumococcal vaccine status was known for 58 of the 125 cases; 13 cases (10%) did receive a pneumococcal 
vaccine prior to illness and 45 cases (36%) had no record of a pneumococcal vaccine.  Vaccine status is not 
known for 67 cases (54%). 
 
Of the 13 confirmed to have received a pneumococcal vaccine, 11 were Alaska Native and 2 non-Native.  
Seven vaccine recipients were from the Anchorage area, 4 were from the YK Delta, 1 from Bristol Bay and 1 
from the Interior.  Ages of vaccine recipients ranged from 4 months to 94 years, however 11 of the 13 vaccine 
recipients were over the age of 35.  It is unknown if these individuals received the 7-valent or 23-valent 
vaccine.   
 
Three (23%) of the 13 deaths due to S. pneumoniae were due to serotypes found in the PCV7 vaccine.  
However, none of these occurred in persons in the age group for which vaccine is recommended.   Eight  
(61%) of the fatal cases were due to serotypes contained within the 23 valent polysaccharide vaccine;  5 of 
these occurred in persons in the age group eligible for this vaccine.  Vaccination status was known for only 1 
of the 13 deaths. 
 
Invasive Streptococcus pneumoniae Serotypes of Fatal Cases – Alaska, 2000 
Serotype Deaths (%) Frequency of Serotype 
03 3 (50%) 6  
04 1 (8%) 13  
06A 2 (50%) 4  
09V 1 (11%) 9  
11A 1 (50%) 2  
13 1 (100%) 1  
19F 1 (14%) 7  
20 1 (100%) 1  
35B 1 (100%) 1  
38 1 (100%) 1  
Total 13 (12%) 109  
 
Overall, 62% of all pneumococcal-related mortality was potentially vaccine preventable with the use of the 
23-valent polysaccharide vaccine in persons over 2 years old.   
 
Potentially Vaccine Preventable Deaths 
 < 2 years 2 – 4 5 - 54 55 - 64 65+ Total 
PCV7 - -  - 1 (50%) 2 (25%) 3 (23%) 
Ps23V - - 3 (100%) 1 (50%) 4 (50%) 8 (62%) 
Note: The number in parentheses is the percentage of cases with a serotype in the indicated vaccine,  
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Serotype by Region 
Serotype Anchorage YK Delta Bristol Bay Kotzebue Southeast Interior Norton Sound 
01 3 1     1 
03 4 2      
04 4 2  6 1   
06A 1 1   2   
06B 3     1  
07F 4     6  
09N      1  
09V 5 3    1  
10A 1       
11A 1     1  
13 1       
14 7 7   4  1 
15A  1      
16F 2       
17F  1      
18C 3    1   
19A 2       
19F 6     1  
20 1       
22A  1      
22F 4     1  
23F  1    2  
33F 1       
35B 1       
35F 1       
38 1       
Non-typeable  3 1     




   
Serotype 14 was the most frequently occurring serotype in the YK Delta, Southeast and Anchorage regions.  
In the Southeast region, it was responsible for 50% of all reported cases.  In the YK Delta and Anchorage 
regions, 30% and 13%, respectively, of invasive pneumococcal isolates received by AIP were determined to 
be serotype 14.   
 
Additionally, serotype 14 was the most common type found among young children.  Children under 2 years 
of age infected with invasive Streptococcus pneumoniae had a relative risk of 3.7 of being infected with 
serotype 14 compared with cases 2 years and older.  Sixty-three percent of serotype 14 isolates were found in 
this age group.    
 
Serotype 14 by Age Group  
 Proportion infected 
with Serotype 14  
Percentage with 
Serotype 14 
Under 2 years 12/33 36% 




All 6 isolates received from the Kotzebue region were of serotype 04.  Four of the cases occurred between 
September 6 and October 16, 2000 (one case occurred in March, the other in late July). 
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Interior 
 
Forty-three percent (6 of 14 cases) of reported invasive pneumococcal cases from the Interior region were of 
serotype 07F.  Two isolates were determined to be serotype 23F and the remaining 12 were all of different 
serotypes. 
 
Associated Medical Conditions  
 
The presence of one or more associated medical conditions was reported in 58% of invasive pneumococcal 
cases in 2000.  Data on associated medical conditions was unavailable for 8% (10 cases).   Excessive alcohol 
use was indicated for 31% of adult cases (19 years and older), and smoking and excessive alcohol use were 
reported together for 18% of adult patients (11 cases).   Injection drug use was reported in 3 cases (5% of 
adult cases).  Chronic lung disease was reported as a risk factor for 21 cases, or 17%.   
 
Associated Medical Conditions Identified in Invasive Pneumococcal Cases in Alaska, 2000* 
Associated Medical Condition No. Cases (%), N=125 No. Adult Cases (%), N=65 
Diabetes 13 (10%) 13 (20%) 
Cigarette smoking 25 (20%) 25 (38%) 
Chronic lung disease 21 (17%) 14 (22%) 
Alcohol abuse 20 (16%) 20 (31%) 
Immunosuppressive treatment 6 (5%) 5 (8%) 
Injection drug use 3 (2%) 3 (5%) 
Cigarette smoking only 8 (6%) 8 (12%) 
*More than one risk factor was identified in several cases. 
 
Twenty-five (38%) of the 65 adult cases were known cigarette smokers.  According to the 2000 BRFSS 
survey, the rate of smoking in the state of Alaska for persons aged 18 and older in 2000 was 25% (MMWR, 
December 14, 2001, Vol.50, No. 49).     
 
Invasive Pneumococcal Cases with Known Cigarette  
Smoking Status, by Age and Race 
 




Susceptibility testing was performed on 106 isolates.  Of these, 23% showed decreased susceptibility to 
penicillin.  Decreased susceptibility to trimethoprim/sulfamethoxazole (TMP-sulfa) was found in 32% of the 
106 isolates and 21% demonstrated a decreased susceptibility to erythromycin. Little or no resistance was 
discovered to ofloxacin, chloramphenicol, vancomycin, clindamycin, or rifampin.    
 
Cut points from the Minimum Inhibitory Concentration (MIC) Interpretive Standards were used to determine 
if an isolate was ‘susceptible’, ‘intermediate’, or ‘resistant’ to the antibiotic being tested (National Committee 
for Clinical Laboratory Standards (NCCLS) MIC Testing, Supplemental Tables, M100-S10 (M7), January 
2000).  The MIC Interpretive Standards definitions of ‘susceptible’, ‘intermediate’, and ‘resistant’ can be 
found in the appendix. 
 
Age (yrs) Alaska Native  Non-Native 
 Smokers (%)* Smokers (%)* 
19-44 6 (60%) 4 (40%) 
45-54 0 (0%) 5 (56%) 
55-64 4 (100%) 3 (100%) 
65+ 0 (0%) 3 (30%) 
Total 10(43%) 15 (39%) 
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Antibiotic Resistance in Invasive Streptococcus pneumoniae Isolates – Alaska, 2000 
Antibiotic Susceptible Intermediate Resistant I + R Total Tested 
Penicillin 81 (76.4%) 11 (10.3%) 14 (13.2%) 25 (23.6%) 106 
TMP-sulfa 72 (67.9%) 4 (3.8%) 30 (28.3%) 34 (32.1%) 106 
Erythromycin 84 (79.2%) 0 22 (20.8%) 22 (20.8%) 106 
Ofloxacin 106 (100%) 0 0  106 
Chloramphenicol 104 (98%) 0 2 (2%) 2 (2%) 106 
Vancomycin 106 (100%) 0 0  106 
Clindamycin 35 (97%) 0 1 (3%) 1 (3%) 36 
Rifampin 103 (100%) 0 0  103 
 
Serotypes found in the PCV7 vaccine are more likely to be nonsusceptible to penicillin and erythromycin than 
non-vaccine serotypes.  One potential benefit of the vaccine is an anticipated decline in antibiotic resistance 
among circulating pneumococci. 
 
PCV7 Serotypes and Resistance to Selected Antibiotics - Alaska, 2000 




+Resistant # (%) 
Total  Resistant # (%) Total 
04 0 (0%) 0 (0%) 13 0 (0%) 13 
6B 1 (33%) 2 (66%) 3 2 (66%) 3 
9V 4 (44%) 7 (78%) 9 3 (33%) 9 
14 7 (37%) 9 (47%) 19 13 (72%) 19 
18C 0 (0%) 0 (0%) 4 0 (0%) 4 
19F 2 (29%) 2 (29%) 7 2 (29%) 7 
23F 0 (0%) 1 (33%) 3 2 (67%) 3 
Total 14 (24%) 21 (36%) 58 22 (38%) 58 
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A total of 16 cases of invasive Haemophilus influenzae were reported to AIP in 2000, resulting in an overall 
rate for the state of Alaska in 2000 of 2.6/100,000 persons per year.  The 2000 Alaska rate is more than twice 
the ABCs national projected rate of 1.2/100,000 (Active Bacterial Core Surveillance (ABCs) Report 
Emerging Infections Program Network Haemophilus influenzae, 2000).  However, in a relatively small 
population, one year trends are subject to wide variability.  A fair comparison with national rates should be 
made using multiple years of data.  There were 4 invasive Haemophilus influenzae-related deaths in Alaska in 
2000, resulting in a case-fatality rate of 25%, and an overall Haemophilus influenzae mortality rate of 
0.6/100,000 persons per year for Alaska.  In contrast, the 2000 ABCs national projected mortality rate for 




Invasive Haemophilus influenzae, by Month of 
































































Invasive Haemophilus influenzae Cases, by Race 
Racial Group Cases 
No.  (%) 
Rate* % Male Deaths 
Alaska Native 10 (63%) 9.2 50% 2 
Non-Native**   6 (38%) 1.2   0% 2 
Total 16 (100%) 2.6 31% 4 
*Rate per 100,000 population: population figures calculated from Census 2000 data:  
  Alaska Native: 108,187, Non-Natives: 518,745 
**Unknown race (n=1) included in Non-Native group 
 
Sixty-three percent of invasive Haemophilus influenzae cases occurred among the Alaska Native population.   
The rate ratio of disease for the Alaska Native population, compared with the non-Native population, is 7.6, 




Residents of Anchorage accounted for 38% (6 cases) of invasive Haemophilus influenzae in 2000.  One case 
each occurred in the following communities located throughout the state of Alaska: Fairbanks, Soldotna, 
Kwetheluk, Seward, Homer, Dillingham, New Stuyahok, Tok, Brevig, and Little Diomede.  
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Age 
 
Invasive Haemophilus influenzae,  by Race and Age Group -





























Invasive Haemophilus influenzae cases ranged in age from infancy to 80 years.   Dramatically more disease 
occurred among Alaska Native children under 2 years of age.  The Alaska Native rate for children <2 was 
124.4/100,000, compared with a rate of 6.5/100,000 for non-Native children of the same age.   
 





































In 2000, the rate of invasive Haemophilus influenzae in females in Alaska was more than twice that of males, 




The primary clinical presentation was determined by a review of the discharge diagnoses indicated in each 
patient’s chart.  In cases with multiple discharge diagnoses, the most serious Haemophilus influenzae-related 
diagnosis was recorded as the primary clinical presentation. 
 
Pneumonia was the most common primary clinical presentation, occurring in 9 (56%) of the invasive 
Haemophilus influenzae cases in 2000.  Meningitis and septicemia of unknown focus were each diagnosed in 
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3, or 19%, of cases.  One patient presented with septic arthritis. This patient also presented with osteomyelitis.   
No other cases were diagnosed with a secondary invasive Haemophilus influenzae-related syndrome. 
 
Primary Clinical Presentations of Invasive Haemophilus 
 influenzae – Alaska, 2000 
Primary Presentation Cases  
No. (%) 
Deaths 
Meningitis 3 (19%) - 
Pneumonia 9 (56%) 2 
Septic Arthritis 1 (6%) - 
Septicemia 3 (19%) 2 
Total 16 (100%) 4 
 
 
Haemophilus influenzae was isolated from blood samples in 14 of 16 cases (88%).   Two cases were 




Four patients died due to infection with invasive Haemophilus influenzae, resulting in a case-fatality rate for 
the state of Alaska in 2000 of 25% (4 deaths out of 16 cases).   The overall invasive Haemophilus influenzae-
related mortality rate for Alaska is 0.6/100,000 persons per year – three times the national projected mortality 
rate of 0.2/100,000 (Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program 
Network Haemophilus influenzae, 2000 (preliminary)). 
 
Those who died ranged from newborn to 69 years old.  Two cases resulting in death (50%) were residents of 
Anchorage, one case was from rural South Central and the other from the rural Bristol Bay area.  Two cases 
were non-Native and two were Alaska Native.  One associated medical condition was identified for each of 3 
cases: alcoholism, diabetes, and chronic lung disease.  The only male case, a newborn Alaska Native, had no 
known associated medical conditions.  Antibiotic susceptibility testing was performed on 3 of the isolates; no 
antibiotic resistance was detected.   Serotyping was also performed on the 3 isolates: 1 was serotype B, the 




Serotyping is performed on all isolates sent to AIP.  The bacterial capsule forms the basis for typing 
and is the major virulence factor.  Type B is historically more prevalent and invasive, but due to 
routine childhood vaccination has decline by more than 90% since the 1980’s.  Continued 
surveillance is important to evaluate vaccine effectiveness and to monitor for the emergence of non-
vaccine types. 
 
Serotypes of Invasive Haemophilus influenzae Cases, by Race 
 - Alaska, 2000  
Serotype Alaska Native Non-Native Unknown Total (%) 
B 6 3 - 9 (56%) 
E - 1 - 1 (6%) 
F 1 - 1 2 (13%) 
NT* 3 1 - 4 (19%) 
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Antibiotic susceptibility testing for chloramphenicol, ceftriaxone, and trimethoprim/sulfamethoxazole was 
performed on 15 isolates (94% of cases) at the AIP laboratory in Anchorage, Alaska.  No resistance was 
detected to chloramphenicol and ceftriaxone.  One isolate (7%) demonstrated resistance to 
trimethoprim/sulfamethoxazole.   
 
 
Antibiotic Resistance of Invasive Haemophilus influenzae  
Isolates - Alaska, 2000 
Antibiotic Susceptible Intermediate Resistant 
Chloramphenicol 15 (100%) - - 
Ceftriaxone 15 (100%) - - 
TMP/sulfa 14 (93%) - 1 (7%) 
      
 
Age Group B (rate)*  Non-B (rate) Non-Type** (rate) Unknown Total (rate) 
<2 5 (24.7) - 2 (9.9) - 7 (34.6) 
2-64 3 (0.5) 2 (0.4) 1 (0.2) 1 (0.2) 7 (1.2) 
65+ 1 (2.9) 1 (2.9) - - 2 (5.9) 
Total 9 (1.4) 3 (0.5) 3 (0.5) 1 (0.2) 16 (2.55) 
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Serotype Associated Medical Conditions Outcome 
Male 1 day AK Native Other Blood Septicemia - NT - Death 
Female 0.3 AK Native Other CSF Meningitis - B -  
Female 0.3 AK Native Other CSF Meningitis - B -  
Male 0.4 AK Native Other Blood Pneumonia - B Chronic lung disease  
Male 0.6 AK Native Anchorage Blood Septicemia - B -  
Male 0.8 AK Native Other Blood Meningitis - NT* -  
Female 1 Non-Native Other Blood Septic Arthritis Osteomyelitis B -  
Female 4 AK Native Other Blood Pneumonia - B Imm tx**  
Male 13 AK Native Anchorage Blood Pneumonia - B -  
Female 53 AK Native Anchorage Blood Pneumonia - F Cigarette smoking + chronic lung 
disease + alcohol 
 
Female 54 AK Native Anchorage Blood Septicemia -  Alcohol Death 
Female 55 Non-Native Other Blood Pneumonia - NT Chronic lung disease Death 
Female 57 Unknown Other Blood Pneumonia - F Smoking + Chronic lung disease  
Female 62 Non-Native Anchorage Blood Pneumonia - B Cigarette smoking  
Female 69 Non-Native Anchorage Blood Pneumonia - B Diabetes Death 
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Haemophilus influenzae Type B (Hib) 
 
 
The most common serotype of invasive Haemophilus influenzae in 2000 was serotype B, accounting for 56% 
of all reported cases.  The rate of Haemophilus influenzae type B (Hib) in Alaska was 1.4/100,000 persons 
per year, significantly higher than the ABCs national projected rate of 0.1/100,000 persons per year (Active 
Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network Haemophilus influenzae, 
2000).    However, in a relatively small population, one year trends are subject to wide variability.  A fair 
comparison with national rates should be made using multiple years of data.  Among children under 2 years 
of age diagnosed with invasive Haemophilus influenzae, 71% were infected with serotype B.   
 






























One-third of reported Hib cases in Alaska in the year 2000 occurred among the non-Native 
population, for an overall Hib rate for non-Natives of 1.2/100,000 persons per year.  In contrast, the 
rate of invasive Hib disease among the Alaska Native population in 2000 was 2.8/100,000 persons 
per year.  The rate ratio of disease for the Alaska Native population compared with the non-Native 
population is 2.3. 
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A total of 9 cases of invasive Neisseria meningitidis were reported to AIP in Anchorage, Alaska in 2000, 
resulting in an overall rate for the state of Alaska in 2000 of 1.4/100,000 persons per year.  The Alaska rate is 
almost twice the ABCs 2000 national projected rate of 0.8/100,000 (Active Bacterial Core Surveillance 
(ABCs) Report Emerging Infections Program Network Neisseria meningitidis, 2000).  There were no invasive 
Neisseria meningitidis-related deaths in Alaska in 2000.  The ABCs National projected Neisseria 
meningitidis-related mortality rate is 0.1/100,000 persons per year for 2000.  However, in a relatively small 
population, one year trends are subject to wide variability.  A fair comparison with national rates should be 




Invasive Neisseria meningitidis, by Month of 































































Invasive Neisseria meningitidis, by Race 
Racial Group Cases 
No.  (%) 
Rate* % Male 
Alaska Native 3 (33%) 2.8 67% 
Non-Native** 6 (67%) 1.2 83% 
Total 9 (100%) 1.4 78% 
*Rate per 100,000 population: population figures calculated from 
  Census 2000 data: Alaska Native: 108,187, non-Native: 518,745 
**Unknown race (n=1) included in non-Native group 
 
The relative risk of disease for Alaska Native population compared with the non-Native population is 2.4, 




Residents of Anchorage accounted for 56% (5 cases) of invasive Neisseria meningitidis in 2000.  The 
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Age 
 
Invasive Neisseria meningitidis,  by Age 
























Invasive Neisseria meningitidis cases ranged in age from 1 year to 64 years old.  Fifty-six percent of cases (5 
of 9 cases) occurred among children under 14 years of age.  No cases were reported among Alaskans over 65.  
  
Rate of Invasive Neisseria meningitidis, 






























   
Sex 
 
In 2000, the rate of invasive Neisseria meningitidis in males in Alaska was 4 times that of females, 








The primary clinical presentation was determined by a review of the discharge diagnoses indicated in each 
patient’s chart.  In cases with multiple discharge diagnoses, the most serious diagnosis related to the Neisseria 
meningitidis infection was recorded as the primary clinical presentation.  In cases with multiple discharge 
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diagnoses, the most serious Neisseria meningitidis-related diagnosis was recorded as the primary clinical 
presentation. 
 
Meningitis was the most common primary clinical presentation, occurring in 5, or 56%, of the invasive 
Neisseria meningitidis cases in 2000.  Septicemia of unknown focus was diagnosed in 2, or 22%, of cases.  
One patient each was diagnosed with septic shock and bacteremia.   One patient that presented with 
meningitis was also diagnosed with pneumonia.  No other cases were diagnosed with a secondary invasive 
Neisseria meningitidis-related syndrome. 
 
 
Primary Clinical Presentations of Invasive  
Neisseria meningitidis – Alaska, 2000 
Primary Presentation Cases  
No. (%) 
Meningitis 5 (56%) 
Septic Shock 1 (11%) 
Bacteremia 1 (11%) 
Septicemia 2 (22%) 
Total 9 (100%) 
 
 
Neisseria meningitidis was isolated from blood samples in 6 of 9 cases (67%).   Three cases were identified 
through the isolation of Neisseria meningitidis from cerebrospinal fluid.   
 
Summary of Invasive Neisseria meningitidis Case Characteristics – Alaska, 2000 










Female 1 AK Native Other Blood Septicemia - - 
Male 2 Non-Native Other CSF Meningitis - - 
Male 7 Non-Native Anchorage Blood Sepsis/Septic Shock - - 
Male 12 AK Native Anchorage Blood Meningitis Pneumonia - 
Male 13 AK Native Other CSF Meningitis - - 
Male 22 Non-Native Other Blood Meningitis - Alcohol + cigarette 
smoking 
Female 23 Non-Native Anchorage CSF Meningitis - - 
Male 55 Non-Native Anchorage Blood Septicemia - Diabetes 
Male 64 Non-Native Anchorage Blood Bacteremia - Cigarette smoking 
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In the year 2000, a total of 18 cases of invasive Group A Streptococcus (GAS) were reported to AIP resulting 
in an overall rate of invasive GAS for the State of Alaska in 2000 of 2.9/100,000 persons per year.  This is 
slightly lower than the ABCs 2000 national projected rate of 3.2/100,000 persons per year (Active Bacterial 
Core Surveillance (ABCs) Report Emerging Infections Program Network group A streptococcus, 2000).  
However, in a relatively small population, one year trends are subject to wide variability.  A fair comparison 
with national rates should be made using multiple years of data. There was 1 invasive GAS-related death in 
Alaska in 2000, resulting in a case-fatality rate of 5.5%, and an overall GAS mortality rate of 0.16/100,000 




Ninety-four percent of invasive GAS cases were identified in the first 8 months of 2000; 17 cases occurred 
between January and August 2000.   
 

































































A total of 10 cases of invasive GAS were reported in the Alaska Native population in 2000, resulting in a case 
rate of 9.2/100,000 for this population.  In contrast, the rate of invasive GAS among non-Natives for the same 
time period is 1.6/100,000 (8 cases).    
 
Invasive GAS Cases, by Race - Alaska, 2000 
Racial Group Cases 
No.  (%) 
Rate* % Male Deaths 
Alaska Native 10 (56%) 9.24 50% - 
Non-Native   8 (44%) 1.54  63% 1 
Total 18 (100%) 2.9 63% 1 
*Rate per 100,000 population: population figures calculated from Census 2000  
data: Alaska Native: 108,187, non -Native: 518,745 
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Region 
 
Anchorage carried the bulk of the invasive GAS burden in Alaska in 2000, 61% of cases (11) occurred among 




In 2000, the rate of invasive GAS among males was 3.3/100,000 (10 cases).  For females, the rate of invasive 




Cases ranged in age from 6 months to 77 years, with 50% occurring between the ages of 19 – 44.  Seventeen 
percent of cases occurred among individuals in the 45 – 54 year old age group.  No cases were reported in 
children 5 – 18 years old.    
 
The highest rates of disease occurred among AK Natives under the age of 2 years and those over the age of 



















The primary clinical presentation was determined by a review of the discharge diagnoses indicated in each 
patient’s chart.  In cases with multiple discharge diagnoses, the most serious GAS-related diagnosis was 
recorded as the primary clinical presentation. 
 
Of the 18 cases identified in 2000, 5 experienced multiple GAS-related presentations.   In addition to the 
primary presentation, 2 cases were diagnosed with cellulitis, 1 with pneumonia and 1 additional diagnosis 
was unspecified.  The patient who died was diagnosed with secondary endocarditis and septic arthritis, as 
well as the primary diagnosis of sepsis/septic shock. 
 
Rate of Invasive Group A Streptococcus , by Race and Age 
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Primary Clinical Presentations  





Empyema 1 (5.5%) 
Septic Shock 1 (5.5%) 
Cellulitis 4 (22.5%) 
Peritonitis 1 (5.5%) 
Osteomyelitis 1 (5.5%) 
Pneumonia 2 (11%) 
Septic Arthritis 2 (11%) 
Bacteremia 1 (5.5%) 
Septicemia 4 (22.5%) 
Other 1 (5.5%) 
Total 18  
 
GAS was identified in blood samples of 78% of cases (14).  The remaining cases were identified through 
pleural fluid (1), joint fluid (2), and one unspecified sterile site.  
 
Associated Medical Conditions 
 
The most common associated medical conditions identified among the 18 Alaska GAS cases in 2000 were 
reported alcohol abuse (4 cases, 22%) and immunosuppressive treatment (4 cases, 22%).   No associated 
medical conditions were indicated for 50% of cases (9).   
 
Associated Medical Conditions Identified in Invasive  
GAS Cases in Alaska, 2000 
Associated medical condition No. Cases* 
Diabetes 1 
Cigarette smoking 3 
Chronic lung disease 1 
Alcohol abuse 4 
Immunosuppressive treatment 4 
Injection drug use 1 
No associated medical conditions noted 9 




In 2000, the overall case fatality rate for invasive GAS in the state of Alaska was 5.5%, or one death out of a 
total of 18 cases.  
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Summary of Invasive Group A Streptococcus Case Characteristics – Alaska, 2000 
Gender Age Race Anchorage 
/Other 







Female 6 months AK Native Anchorage Blood Septicemia - - - 
Male 2 Non-Native Anchorage Blood Bacteremia - - - 
Male 2 Non-Native Anchorage Pleural fluid Other - - - 
Female 20 AK Native Other Blood Septicemia - Cigarette Smoking + Imm Tx - 
Female 22 AK Native Anchorage Blood Pneumonia Cellulitis Alcohol + Inj Drug - 
Male 23 AK Native Other Joint fluid Osteomyelitis Other Cigarette Smoking  + Alcohol - 
Female 26 AK Native Anchorage Blood Cellulitis - Imm Tx - 
Female 27 Non-Native Other Blood Peritonitis - - - 
Male 30 AK Native Anchorage Joint fluid Cellulitis - - - 
Female 32 Non-Native Anchorage Blood Septic Shock Endocarditis, Septic 
Arthritis 
Imm Tx* Death 
Male 39 AK Native Anchorage Blood Septic Arthritis - Cigarette Smoking + Alcohol - 
Female 44 Non-Native Other Blood Cellulitis - Imm Tx - 
Male 47 Non-Native Anchorage Blood Septicemia - - - 
Male 51 Non-Native Anchorage Blood Septicemia - Alcohol - 
Male 52 AK Native Other Blood Septic arthritis Cellulitis - - 
Female 57 AK Native Anchorage Blood Cellulitis - - - 
Male 74 Non-Native Other Blood Pneumonia - Chronic Lung Dx + Diabetes - 
Male 77 AK Native Other Unspecified 
sterile site 
Empyema Pneumonia - - 
*Immunosuppressive treatment 
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A total of 18 cases of invasive Group B Streptococcus (GBS) were reported to AIP in 2000, resulting in an 
overall rate for the state of Alaska in 2000 of 2.9/100,000 persons per year.  This is lower than the rate of 
6.9/100,000 found in the CDC ABCs areas in 2000 and the national projected rate of 6.8/100,000 (Active 
Bacterial Core Surveillance (ABCs) Report Emerging Infections Program Network group B streptococcus, 
2000).  However, in a relatively small population, one year trends are subject to wide variability.  A fair 
comparison with national rates should be made using multiple years of data.  There were 2 invasive GBS-
related deaths in Alaska in 2000, resulting in a case-fatality rate of 11%, and an overall GBS mortality rate of 






































































GBS Cases by Race – Alaska, 2000 
Racial Group Cases 
No. (%) 
Rate* % Male No. Deaths 
Alaska Native 3 (17%) 2.8 66% - 
Non-Native 15 (83%) 2.9 9% 2 
Total 18 2.9 17% 2 
*Rate per 100,000 population: population figures calculated from Census 2000 data: Alaska  
  Native: 108,187, non-Native: 518,745 




Invasive GBS cases were identified in 8 Alaska communities.  Half of all reported cases occurred in residents 
of Anchorage.  Two cases each were reported in Wasilla and Fairbanks.  The remaining 5 cases occurred in 5 
separate communities. 
 




Invasive Group B Streptococcus,  by Age 
























Non-Native children under 2 years of age carried the bulk of the invasive GBS burden in Alaska in 2000.  
One-third of all reported cases occurred in this age and racial group, resulting in a rate of 39/100,000 for non-
Native children less than 2 years of age.   There were no cases reported in Alaska Native children less than 2 
years of age, and no cases in any children from 2 – 20 years of age.  The rate of invasive GBS for both the 
Alaska Native and non-Native populations between 2- 65 years is less than 2/100,000 in 2000.    
 
Rate of Invasive GBS, by Race and Age, Alaska 2000 
 <2 years 
Rate* (no.) 




Alaska Native 0 1.85 (2) 17.3 (1) 
Non-Native 39.0 (6) 1.26 (6) 10.7 (3) 
*Rate per 100,000 population: population figures calculated from Census 2000 data:  
  Alaska Native: 108,187, non-Native: 518,745 
**Unknown race (n=2) included in non-Native group 
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Invasive GBS Cases Among Children Under 2 Years of 





























The rate of invasive GBS for Alaska females in 2000 was 1.98/100,000 (6 cases).   The rate of invasive GBS 




The primary clinical presentation was determined by a review of the discharge diagnoses indicated in each 
patient’s chart.  In cases with multiple discharge diagnoses, the most serious diagnosis related to the GBS 
infection was recorded as the primary clinical presentation.  Septicemia of unknown focus was the most 
common primary clinical presentation, occurring in 8, or 44%, of the invasive GBS cases in 2000.  Cellulitis 
occurred in 4, or 22%, of cases.  The remaining patients presented with pneumonia, peritonitis, meningitis, 
and bacteremia.   
 
 




No.  (%) 
Deaths 
Bacteremia 1 (6%) - 
Meningitis 1 (6%) - 
Peritonitis 2 (11%) 1 
Cellulitis 4 (22%) - 
Pneumonia 2 (11%) - 
Septicemia 8 (44%) 1 
Total 18 (100%) 2 
 
 
Two cases were diagnosed with an additional GBS-related presentation.  One patient with cellulitis also 
presented with osteomyelitis and one patient with a primary diagnosis of pneumonia also presented with 
cellulitis. 
 
Group B Streptococcus was isolated from blood samples in 15 of 18 cases (83%).   One case each was 
identified through the isolation of the GBS bacteria from cerebrospinal fluid, peritoneal fluid, and tissue.   
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Mortality 
 
Two of 18 cases died due to infection with invasive GBS, for an overall case fatality rate of 11%.  The overall 
GBS-related mortality rate for Alaska is 0.3/100,000, less than half that projected as the national mortality 
rate of 0.7/100,000 (Active Bacterial Core Surveillance (ABCs) Report Emerging Infections Program 
Network group B streptococcus, 2000).  However, year to year rates in a small population are likely to vary 
widely and multiple years would be needed to make a fair comparison.   
 
Associated Medical Conditions 
 
The presence of one or more associated medical conditions was noted in 33% of reported invasive GBS cases 
in 2000.   One associated medical condition was identified in 5 of 6 cases and 3 (diabetes, alcohol use, and 
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Female 1 day Non-Native Anchorage Blood Septicemia - - - 
Male 1 day Non-Native Anchorage Blood Septicemia - - - 
Male 1 day Non-Native Other Blood Pneumonia - - - 
Female 10 days Non-Native Anchorage CSF Meningitis - - - 
Male 0.1 Non-Native Other Blood Septicemia - - - 
Female 0.5 Non-Native Other Blood Septicemia - - - 
Male 43 Non-Native Other Peritoneal fluid Peritonitis - Alcohol Death 
Male 46 Non-Native Anchorage Blood Septicemia - - - 
Female 49 Non-Native Anchorage Blood Cellulitis - - - 
Male 49 AK Native Other Joint Fluid Cellulitis Osteomyelitis - - 
Male 50 Non-Native Other Blood Septicemia - Alcohol Death 
Male 55 AK Native Anchorage Blood Peritonitis - Diabetes + alcohol + smoking - 
Male 59 Non-Native Other Blood Cellulitis - Diabetes  - 
Male 62 Non-Native Anchorage Blood Septicemia - Chronic lung disease - 
Male 66 Non-Native Other Blood Cellulitis - Diabetes - 
Female 76 AK Native Anchorage Blood Septicemia - - - 
Female 78 Non-Native Other  Blood Bacteremia - Unknown - 
Male 86 Non-Native Anchorage Blood Pneumonia Cellulitis - - 




MIC Interpretive Standards Definitions:  
 
 NCCLS provides recommended interpretive categories for various Minimum Inhibitory Concentration values 
(cut points) for each organism which are defined as follows:* 
 
 1.  Susceptible (S):   
 
The “susceptible” category implies that an infection due to the strain may be appropriately treated 
with the dosage of antimicrobial agent recommended for that type of infection and infecting species, 
unless otherwise contraindicated. 
 
2.  Intermediate (I):   
 
The “intermediate” category includes isolates with antimicrobial agent MICs that approach usually 
attainable blood and tissue levels and for which response rates may be lower than for susceptible 
isolates.  The “intermediate” category implies clinical applicability in body sites where the drugs are 
physiologically concentrated (e.g., quinolones and β-lactams in urine) or when a high dosage of a 
drug can be used (e.g., β-lactams).  The “intermediate” category also includes a buffer zone which 
should prevent small, uncontrolled technical factors from causing major discrepancies in 
interpretations, especially for drugs with a narrow pharmacotoxicity margins. 
 
 
3.  Resistant (R):   
 
Resistant strains are not inhibited by the usually achievable systemic concentrations of the agent with 
normal dosage schedules and/or fall in the range where specific microbial resistance mechanisms are 
likely (e.g., β-lactamases) and clinical efficacy has not been reliable in treatment studies.  
 
 
* NCCLS, MIC Testing, Supplemental Tables, M100-S10 (M&), January 2000, p.9.   
